Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients.
作者信息
Destras Grégory, Bal Antonin, Simon Bruno, Lina Bruno, Josset Laurence
机构信息
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-69004 Lyon, France; GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS de Lyon, Lyon, France.
Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-69004 Lyon, France; GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
出版信息
Lancet Microbe. 2022 Aug;3(8):e559. doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.
Abstract
摘要
相似文献
1
Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients.索托维单抗促使免疫功能低下患者体内的新冠病毒奥密克戎变种发生进化。
Lancet Microbe. 2022 Aug;3(8):e559. doi: 10.1016/S2666-5247(22)00120-3. Epub 2022 May 27.
2
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab.接受索托维单抗治疗患者中新冠病毒奥密克戎变体的耐药突变
Clin Microbiol Infect. 2022 Sep;28(9):1297-1299. doi: 10.1016/j.cmi.2022.05.002. Epub 2022 May 17.
3
[Sotrovimab in controlling SARS-CoV-2 infection].[索托维单抗在控制新型冠状病毒2感染中的作用]
Pol Merkur Lekarski. 2022 Feb 22;50(295):48-50.
4
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.针对严重急性呼吸综合征冠状病毒 2 株 delta 和 omicron 变异株的单克隆抗体的临床疗效和体外中和能力。
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
5
Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.高危人群感染 SARS-CoV-2 奥密克戎变异株后使用索托维单抗治疗出现耐药相关突变。
JAMA. 2022 Sep 20;328(11):1104-1107. doi: 10.1001/jama.2022.13854.
6
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study).索托维单抗治疗轻至中度新冠病毒奥密克戎变异株感染的极高风险患者的结局：一项前瞻性队列研究（法国国家艾滋病研究机构0003S COCOPREV研究）
J Infect. 2022 Jun;84(6):e101-e104. doi: 10.1016/j.jinf.2022.04.010. Epub 2022 Apr 7.
7
Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.两名免疫功能低下的持续性 COVID-19 感染者在抗体治疗后出现刺突突变的演变。
J Med Virol. 2022 Mar;94(3):1241-1245. doi: 10.1002/jmv.27445. Epub 2021 Nov 13.
8
Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.针对 SARS-CoV-2 的治疗与 COVID-19 免疫功能低下患者的死亡率降低有关。
J Antimicrob Chemother. 2022 Sep 30;77(10):2688-2692. doi: 10.1093/jac/dkac253.
9
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.使用索托维单抗后新冠病毒德尔塔变异株中的耐药突变
N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
10
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.中和抗体和抗病毒药物对 SARS-CoV-2 奥密克戎变异株 BA.1 和 BA.2 的不同疗效。
Antiviral Res. 2022 Sep;205:105372. doi: 10.1016/j.antiviral.2022.105372. Epub 2022 Jul 4.
引用本文的文献
1
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials.索特罗维单抗治疗 2019 冠状病毒病（COVID-19）：随机临床试验的系统评价和荟萃分析。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9573-9589. doi: 10.1007/s00210-024-03298-y. Epub 2024 Jul 20.
2
COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases.肺移植受者中的 COVID-19：10 例近期病例报告。
Viruses. 2024 Apr 29;16(5):709. doi: 10.3390/v16050709.
3
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.SARS-CoV-2 对单克隆抗体和小分子药物的耐药性。
Cell Chem Biol. 2024 Apr 18;31(4):632-657. doi: 10.1016/j.chembiol.2024.03.008.
4
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.245例免疫功能低下患者中针对新冠病毒变异株的单克隆抗体疗法的临床和病毒学结果：一项多中心前瞻性队列研究
Clin Infect Dis. 2024 Jun 14;78(6):1514-1521. doi: 10.1093/cid/ciae026.
5
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.索特罗维单抗：对 SARS-CoV-2 变异株疗效的评价。
Viruses. 2024 Jan 31;16(2):217. doi: 10.3390/v16020217.
6
Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient.肾移植受者长期感染期间出现具有双重耐药突变的新型冠状病毒2
Infect Drug Resist. 2024 Feb 8;17:531-541. doi: 10.2147/IDR.S438915. eCollection 2024.
7
An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.关于 SARS-CoV-2 临床试验结果的最新信息——我们可以从中学到什么以应对下一次大流行。
Int J Mol Sci. 2023 Dec 26;25(1):354. doi: 10.3390/ijms25010354.
8
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study.SLE 患者抗 SARS-CoV-2 抗病毒药物和单克隆抗体的疗效和安全性：一项病例对照研究。
Biomolecules. 2023 Aug 22;13(9):1273. doi: 10.3390/biom13091273.
9
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study.瑞德西韦和 SARS-CoV-2 单克隆抗体预防血液系统疾病患者 COVID-19 进展：一项观察性研究。
Pharmacol Rep. 2023 Oct;75(5):1254-1264. doi: 10.1007/s43440-023-00519-8. Epub 2023 Sep 1.
10
Predicting the antigenic evolution of SARS-COV-2 with deep learning.利用深度学习预测 SARS-COV-2 的抗原进化。
Nat Commun. 2023 Jun 13;14(1):3478. doi: 10.1038/s41467-023-39199-6.
本文引用的文献
1
Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation in France.法国奥密克戎变异株流行期间 SARS-CoV-2 合并感染的检测和流行情况。
Nat Commun. 2022 Oct 23;13(1):6316. doi: 10.1038/s41467-022-33910-9.
2
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.接受单克隆抗体治疗的患者对 SARS-CoV-2 奥密克戎亚谱系 BA.1 和 BA.2 的血清中和作用。
Nat Med. 2022 Jun;28(6):1297-1302. doi: 10.1038/s41591-022-01792-5. Epub 2022 Mar 23.
3
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.使用索托维单抗后新冠病毒德尔塔变异株中的耐药突变
N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
4
Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19.巴瑞替尼单药治疗两名免疫功能低下的COVID-19患者。
Lancet Microbe. 2021 Sep;2(9):e424. doi: 10.1016/S2666-5247(21)00189-0. Epub 2021 Jul 28.
Zotero 插件